Use of provider global assessment rather than physician's global assessment cheapens the value of disease activity measures: Comment on the article by Anderson et al


  • John A. Goldman MD, MACR, FACP, CCD

    1. Atlanta, GA
    Search for more papers by this author
    • Dr. Goldman has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Atlanta Center for Clinical Research and UCB and (more than $10,000 each) from Amgen and Pfizer, owns stock or stock options in Bristol-Myers Squibb, and has served as an expert witness in cases involving patients with polymyositis and juvenile idiopathic arthritis.

No abstract is available for this article.